The chief medical officer of VTV Therapeutics Inc., a clinical-stage pharmaceutical company, is leaving the company to pursue other opportunities, according to a Securities and Exchange Commission filing.

The effective date of Larry Altstiel’s departure will be April 30. In connection with his departure, the company and Altstiel agreed to terminate his employment agreement, and they are continuing to discuss the terms of his separation.

Prior to VTV Therapeutics, Altstiel was the CEO of Provectra Therapeutics Inc., and vice president of Pfizer.

VTV Therapeutics was developing an Alzheimer’s drug, Azeliragon, to inhibit the RAGE receptor, ideally to help people with mild Alzheimer’s delay cognitive decline.

The drug’s phase 3 trial concluded in early 2018 but the treatment did not improve in cognitive or functional outcomes. The company is discontinuing its clinical trials.

Earlier this month, shares of VTV Therapeutics plunged 65 percent to $1.14, down $2.12 per share, after it reported that it was discontinuing its trials.

VTV is the latest company to struggle with developing an Alzheimer’s treatment. Others include Merck, Pfizer, and Eli Lilly.

The company closed Friday at $1.95 down 2.5 percent, or 5 cents.